Omalizumab improves lung function in adolescents with allergic asthma

  • Busse WW & al.
  • Ann Allergy Asthma Immunol
  • 21 Nov 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In adolescents with moderate-to-severe uncontrolled asthma, omalizumab was associated with significant improvement in lung function and reduction in eosinophil counts.

Why this matters

  • Findings highlight the potential effect of omalizumab in patients who remain uncontrolled on current therapies and the need for optimizing treatment early in the disease course.

Study design

  • Post-hoc analysis of 8 randomised studies including 340 adolescents who were randomly assigned to receive either omalizumab (n=203) or placebo (n=137) every 2 and 4 weeks for a period between 6 and 12 months.
  • Funding: Genentech, Inc. and others.

Key results

  • Treatment with omalizumab vs placebo was associated with an increase in all baseline lung function:
    • Least squares mean (LSM) change from baseline in percent predicted forced expiratory volume in 1 second (ppFEV1): 3.0%; 95% CI, 0.2%-5.7%; P=.035
    • LSM change from baseline in FEV1: 120.9 mL; 95% CI, 30.6-211.2 mL; P=.009 and
    • LSM change from baseline in forced vital capacity: 101.5 mL; 95% CI, 8.3-194.6 mL; P=.033.
  • Reduction in eosinophil counts was greater with omalizumab vs placebo with an LSM treatment difference of −85.9 cells/μL; 95% CI, −137.1 to −34.6 cells/μL; P=.001).

Limitations

  • Post hoc analysis.